All lobbying filings

RK STRATEGIES, INC.

RK STRATEGIES, INC. filed a Q4 report for CLEARMIND MEDICINE, INC on January 20, 2026, reporting $10,000 in lobbying income.

Lobbying for CLEARMIND MEDICINE, INC · Developer of Psychedelics Medicines

All filings by RK STRATEGIES, INC. · Everything CLEARMIND MEDICINE, INC has reported

Filing · LD-2 quarterly report Q4 report

Reporting period

4th Quarter 2025

Oct 1 - Dec 31 · Posted Jan 20, 2026

Income

$10,000

What the client paid this registrant for the period.

Client based in

British Columbia

Official filing document

Government bodies contacted 3

The chambers, agencies and offices the filer named. It does not say who inside them was contacted, or when. Each name opens every filing that named the same body.

Lobbying activity 4

Defense

Psychedelic Legislation H.R. 7091, Expanding Veterans Access to Emerging Treatments Act H.R.2623, Innovative Therapies Centers of Excellence Act of 2025

Alcohol and Drug Abuse

H.R. 3838, the Streamlining Procurement for Effective Execution and Delivery (SPEED) Act H.R. 7091, Expanding Veterans Access to Emerging Treatments Act H.R.2623, Innovative Therapies Centers of Excellence Act of 2025

Veterans

H.R. 7091, Expanding Veterans Access to Emerging Treatments Act H.R.2623, Innovative Therapies Centers of Excellence Act of 2025 Psychedelics issues

Health Issues

H.R. 7091, Expanding Veterans Access to Emerging Treatments Act H.R.2623, Innovative Therapies Centers of Excellence Act of 2025

Bills named in this filing 3

H.R. 7091
Expanding Veterans’ Access to Emerging Treatments Act
H.R. 2623
Innovative Therapies Centers of Excellence Act of 2025
H.R. 3838
Streamlining Procurement for Effective Execution and Delivery and National Defense Authorization Act for Fiscal Year 20…

Source: federal Lobbying Disclosure Act filing, reproduced as filed. Bills are parsed from the activity descriptions.